Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides

<p>In an acute colitis model, data show statistically significant knockdown of elevated levels of serum TNFα, reductions in tissue TNFα mRNA and improvement in disease activity scores In an acute psoriasis model, data show reductions in tissue IL-17A mRNA and improvement in clinical disease markers including skin lesions BEDMINSTER, N.J, Dec. 27, 2023 (GLOBE NEWSWIRE) […]</p>
<p>The post <a href="https://forextv.com/top-news/matinas-biopharma-demonstrates-in-vivo-biological-activity-and-disease-improvement-in-two-inflammatory-disease-models-with-oral-lnc-delivered-small-oligonucleotides/">Matinas BioPharma Demonstrates in vivo Biological Activity and Disease Improvement in Two Inflammatory Disease Models with Oral LNC-Delivered Small Oligonucleotides</a> appeared first on <a href="https://forextv.com">ForexTV</a>.</p>